复方脑肽节苷脂对急性颅脑损伤患者神经功能的影响  

Effect of compound cerebroside ganglioside on neurological function in patients with acute craniocerebral injury

作　　者：周建海 李键 宋波 ZHOU Jianhai;LI Jian;SONG Bo(Xinhua Hospital,Huainan Xinhua Medical Group,Huainan 232052,China)

机构地区：[1]淮南新华医疗集团新华医院,安徽淮南232052

出　　处：《中国实用神经疾病杂志》2024年第3期347-350,共4页Chinese Journal of Practical Nervous Diseases

基　　金：2019年安徽省重点研究与开发计划项目(编号:201904a07020001)。

摘　　要：目的探讨复方脑肽节苷脂对急性颅脑损伤患者神经功能恢复与相关因子水平的影响。方法选取淮南新华医疗集团新华医院2019-12—2022-10收治的104例急性颅脑损伤患者为研究对象,对照组和观察组各52例。对照组患者给予基础治疗方案:根据患者实际情况,适当给予常规止血、利尿、血压调控、维持水电解质平衡、抗感染、降低颅内压治疗。观察组患者于基础治疗的同时肌内注射复方脑肽节苷脂,2~4 mL/次,2次/d。2组均治疗14 d,比较2组治疗前后的格拉斯哥结局量表(GOSE)、认知障碍评定表(RLA)评分,以及2组治疗前后的血清NPY、CGRP、Tau蛋白、sICAM-1、NSE、FLK-1水平。评价2组不良反应。结果治疗后观察组GOSE、RLA评分分别为(4.53±0.52)分、(6.35±0.62)分,均明显高于同期对照组(P<0.05);血清NPY、CGRP、Tau蛋白、sICAM-1和NSE水平分别为(82.06±6.55)ng/L、(39.25±3.13)ng/L、(250.56±20.01)ng/L、(352.25±28.13)μg/L、(15.23±1.21)μg/L,均较对照组明显降低,差异有统计学意义(P<0.05);血清FLK-1水平为(79.22±6.32)μg/L,显著高于对照组(P<0.05)。2组不良反应发生率无统计学差异(28.84%比23.07%,P>0.05)。结论复方脑肽节苷脂对急性颅脑损伤患者神经功能恢复具有积极的促进作用。Objective To investigate the effect of compound cerebroside ganglioside on the recovery of neurological function and the levels of related factors in patients with acute craniocerebral injury.Methods A total of 104 patients with acute craniocerebral injury admitted to Xinhua Hospital,Huainan Xinhua Medical Group from December 2019 to October 2022 were selected and divided into control group and observation group,with 52 cases in each group.The patients in the control group were given the basic treatment plan,according to the actual situation of the patients,routine hemostasis,diuresis,blood pressure regulation,maintenance of water and electrolyte balance,anti-infection,and reduction of intracranial pressure were appropriately given.At the same time as the basic treatment plan,the observation group was given intramuscular injection of compound cerebroside ganglioside,2-4 mL a time,2 times perday.The treatment time of both groups was 14 days.The GOSE and RLA scores of the two groups were compared before and after treatment.The levels of serum NPY,CGRP,Tau protein,sICAM-1,NSE,and FLK-1 were compared between the two groups before and after treatment.The adverse reactions of the two groups were evaluated.Results After treatment,the observation group showed significantly higher GOSE and RLA scores compared to the control group during the same period(P<0.05),with scores of(4.53±0.52)points and(6.35±0.62)points,respectively.The serum levels of NPY,CGRP,Tau protein,sICAM-1,and NSE in the observation group were significantly lower than those in the control group,with the levels of(82.06±6.55)ng/L,(39.25±3.13)ng/L,(250.56±20.01)ng/L,(352.25±28.13)μg/L,and(15.23±1.21)μg/L,respectively(P<0.05).Additionally,the serum FLK-1 level was significantly higher in the observation group at(79.22±6.32)μg/L compared to the control group during the same period(P<0.05).The incidence of adverse reactions in the two groups showed no statistical difference(28.84%vs 23.07%)(P>0.05).Conclusion Compound cerebroside ganglioside has a p

关 键 词：复方脑肽节苷脂 急性颅脑损伤 神经功能 不良反应 

分 类 号：R651.15[医药卫生—外科学]